▎药明康德

宾夕法尼亚州/费城，2022年8月12日 -- 专注于细胞和基因疗法的CTDMO药明生基今日宣布与强生旗下杨森制药公司所属的杨森生物技术公司（杨森）达成许可协议。根据协议，药明生基将授权杨森使用其先进的TESSA™专利技术。TESSA™技术是一种用于制造腺相关病毒载体（AAV）的高性能系统，通过其生产的AAV是基于传统方法生产的10倍。同时，杨森还可以使用药明生基的专利克隆悬浮HEK293细胞系。该许可协议由强生创新主导。

AAV载体能够转导多种细胞和组织类型，因此成为向患者提供基因治疗的主要工具。药明生基的TESSA™技术可以帮助客户更高效地生产高质量的AAV，来满足行业对大规模AAV生产的需求。药明生基已成功将TESSA™技术的生产规模提升至200L，与基于传统质粒方法生产相比，可生产超过10倍的AAV产量，且完整包装的AAV比例显著提升，大幅降低了AAV的总生产成本。

“很荣幸杨森选择了药明生基的TESSA™技术。”药明生基首席执行官张幼翔博士表示：“我们将持续提升TESSA™平台的能力和规模，提高AAV产品的研发生产效率及可行性，造福全球患者。”

作为一家全球化运营的细胞和基因疗法CTDMO，药明生基将持续加强赋能平台的能力和规模建设，助力合作伙伴推动更多细胞和基因创新疗法早日上市，为患者谋福祉。

关于药明生基

药明生基是药明康德旗下专注于细胞和基因疗法的CTDMO，致力于加速和变革基因和细胞治疗及其他高端治疗的开发、测试、生产和商业化。药明生基能够助力全球客户将更多创新疗法早日推向市场，造福病患。更多信息，请访问 www.wuxiatu.com 。

关于药明康德

药明康德（股票代码：603259.SH/2359.HK）为全球生物医药行业提供一体化、端到端的新药研发和生产服务，在亚洲、欧洲、北美等地均设有运营基地。药明康德通过独特的“CRDMO”和“CTDMO”业务模式，不断降低研发门槛，助力客户提升研发效率，为患者带来更多突破性的治疗方案，服务范围涵盖化学药研发和生产、生物学研究、临床前测试和临床试验研发、细胞及基因疗法研发、测试和生产等领域。2021年，药明康德被MSCI评为ESG（环境、社会及管治）AA级。目前，公司的赋能平台正承载着来自全球30多个国家的5850多家合作伙伴的研发创新项目，致力于将更多新药、好药带给全球病患，早日实现“让天下没有难做的药，难治的病”的愿景。更多信息，请访问公司网站： www.wuxiapptec.com 。

---

WuXi ATU AnnouncesLicensing Agreement with Janssen for TESSA™ Technology

August 11, 2022 – PHILADELPHIA, PA. WuXiAdvanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announceda licensing agreement with Janssen Biotech, Inc., one of the JanssenPharmaceutical Companies of Johnson & Johnson ("Janssen"). Underthis agreement, WuXi ATU will license to Janssen its TESSA™ technology, a high-performancesystem that can produce 10 times more adeno-associated viral (AAV) vectors thantraditional AAV manufacturingsystems. Janssen will also have access to work on WuXi ATU’s proprietary clonal suspension HEK293 cell line. This agreement wasfacilitated by Johnson & Johnson Innovation.

AAVvectors are commonly used for the delivery of gene therapies to patients due totheir ability to transduce numerous cell and tissuetypes. WuXi ATU’s TESSA™ technology responds to industry demand for large scaleAAV manufacturing by producing higher quality AAV particles more efficiently. WuXi ATU hasalso successfully scaled up the TESSA™ technology to 200L; this achieved a 10-foldhigher yield and a significantlyhigher percentage of full AAV capsids, greatly reducing overall AAV productioncosts compared to traditional plasmid-based AAV production systems.

"Weare honored that Janssen selected WuXi ATU’s TESSA™ technology." said Dr. DavidChang, Chief Executive Officer of WuXi Advanced Therapies. "We remaincommitted to improving the TESSA™ platform to producefaster and more cost-effective AAV products for patients."

As aContract Testing, Development and Manufacturing Organization (CTDMO) with globaloperations, WuXi ATU will continue to enhance its capability and capacity to helpcustomers develop and deliver life-changing cell and gene therapies fasterfor patients in need.

 

AboutWuXi Advanced Therapies (WuXi ATU)

As theadvanced therapies business unit of WuXi AppTec, WuXi Advanced Therapies is aContract Testing, Development and Manufacturing Organization (CTDMO) thatoffers integrated platforms to transform the discovery, development, testing,manufacturing, and commercialization of cell and gene therapies. Our servicesand solutions accelerate time to market and support customer programs aroundthe world. For more information, please visit https://www.advancedtherapies.com

 

AboutWuXi AppTec

As aglobal company with operations across Asia, Europe, and North America, WuXiAppTec provides a broad portfolio of R&D and manufacturing services thatenable global pharmaceutical and healthcare industry to advance discoveries anddeliver groundbreaking treatments to patients. Through its unique businessmodels, WuXi AppTec’s integrated, end-to-end services include chemistry drugCRDMO (Contract Research, Development and Manufacturing Organization), biologydiscovery, preclinical testing and clinical research services, cell and genetherapies CTDMO (Contract Testing, Development and Manufacturing Organization),helping customers improve the productivity of advancing healthcare productsthrough cost-effective and efficient solutions. WuXi AppTec received AA ESGrating from MSCI in 2021 and its open-access platform is enabling more than 5,850collaborators from over 30 countries to improve the health of those in need –and to realize the vision that "every drug can be made and every diseasecan be treated." Please visit: http://www.wuxiapptec.com

分享，点赞，在看，聚焦全球生物医药健康创新